Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
18 Febrero 2021 - 6:00AM
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the
“Company”), a clinical-stage biopharmaceutical company focused on
oncology and rare diseases, today announced that Dr. Denise
Scots-Knight, Chief Executive Officer of Mereo, will participate in
a fireside chat at the 10th Annual
SVB Leerink Global Healthcare Conference on Thursday,
February 25, 2021 at 8:00am Eastern Time.
A live audio webcast of the presentation can be
accessed through the Investors section of the Company’s website at
www.mereobiopharma.com/investors. An archived replay of the webcast
will be available on the Company’s website for two weeks following
the live presentation.
About Mereo BioPharmaMereo
BioPharma is a biopharmaceutical company focused on the development
and commercialization of innovative therapeutics that aim to
improve outcomes for oncology and rare diseases. The Company has
developed a portfolio of six clinical stage product candidates.
Mereo’s lead oncology product candidate, etigilimab (Anti-TIGIT),
has recently advanced into an open label Phase 1b/2 basket study
evaluating Anti-TIGIT in combination with an anti-PD-1 in a range
of tumor types including three rare tumors and a number of
gynecological carcinomas including cervical and endometrial
carcinomas. The Company’s second oncology product, navicixizumab,
for the treatment of late line ovarian cancer, has completed a
Phase 1 study and has been partnered with OncXerna Therapeutics,
Inc., formerly Oncologie, Inc. The Company has two rare disease
product candidates: alvelestat for the treatment of severe Alpha-1
antitrypsin deficiency (AATD), which is being investigated in an
ongoing Phase 2 proof-of-concept study in the U.S. and Europe, for
which the Company expects to report top line data in the second
half of 2021, and setrusumab for the treatment of osteogenesis
imperfecta (OI). In September 2020, the FDA granted Rare Pediatric
Disease designation to setrusumab for the treatment of OI.
Following the completion of the Company’s Phase 2b ASTEROID study,
the Company met with both the FDA and the European Medicines Agency
(EMA) to discuss the principles of a design of a single Phase 2/3
registrational pediatric study in OI. In December 2020, the Company
signed a license and collaboration agreement for setrusumab in OI
with Ultragenyx Pharmaceutical Inc.
Forward-Looking StatementsThis
Announcement contains “forward-looking statements.” All statements
other than statements of historical fact contained in this
Announcement are forward-looking statements within the meaning of
Section 27A of the United States Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the United States
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Forward-looking statements usually relate to future events and
anticipated revenues, earnings, cash flows or other aspects of our
operations or operating results. Forward-looking statements are
often identified by the words “believe,” “expect,” “anticipate,”
“plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,”
“estimate,” “outlook” and similar expressions, including the
negative thereof. The absence of these words, however, does not
mean that the statements are not forward-looking. These
forward-looking statements are based on the Company’s current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company’s forward-looking statements
involve known and unknown risks and uncertainties some of which are
significant or beyond its control and assumptions that could cause
actual results to differ materially from the Company’s historical
experience and its present expectations or projections. The
foregoing factors and the other risks and uncertainties that affect
the Company’s business, including those described in its latest
Annual Report on Form 20-F, Reports on Form 6-K and other documents
filed from time to time by the Company with the SEC should be
carefully considered. The Company wishes to caution you not to
place undue reliance on any forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to
publicly update or revise any of our forward-looking statements
after the date they are made, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
Mereo BioPharma Contacts: |
|
|
Mereo |
|
+44 (0)333 023 7300 |
Denise Scots-Knight, Chief Executive Officer |
|
|
Christine Fox, Chief Financial Officer |
|
|
|
|
Burns McClellan (Investor Relations Adviser to
Mereo) |
|
+01 212 213 0006 |
Lee Roth |
|
|
Investors |
|
investors@mereobiopharma.com |
Medicure (TSXV:MPH)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Medicure (TSXV:MPH)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024